Randomized Multicenter Phase III Study Comparing the Rate of Molecular Response 4.5 at 12 Months in Newly Diagnosed Philadelphia Positive Chronic Phase Chronic Myelogenous Leukemia Patients Receiving Either Frontline Nilotinib 600 mg Daily or Nilotinib 600 mg Daily Combined to Pegylated Interferon-alfa 2a (Peg-IFN)

Trial Profile

Randomized Multicenter Phase III Study Comparing the Rate of Molecular Response 4.5 at 12 Months in Newly Diagnosed Philadelphia Positive Chronic Phase Chronic Myelogenous Leukemia Patients Receiving Either Frontline Nilotinib 600 mg Daily or Nilotinib 600 mg Daily Combined to Pegylated Interferon-alfa 2a (Peg-IFN)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Nilotinib (Primary) ; Peginterferon alfa-2a
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms PETALs
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Aug 2014 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019 reported by ClinicalTrials.gov.
    • 06 Aug 2014 Planned primary completion date changed from 1 Jul 2015 to 1 Jan 2018 reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top